clinical_research

San Francisco – September 13, 2026 -- Cionic reported that the first 60 participants in its TRANSFORM study showed an average 26% improvement in health-related quality of life after one month, using the standardized EQ-5D-5L instrument across all five measured dimensions.

Cionic launches 12-month study tracking 1,000 adults with upper motor neuron conditions

The TRANSFORM study follows 1,000 adults with multiple sclerosis, stroke, spinal cord injury, cerebral palsy, and related conditions over 12 months, collecting quality-of-life data through six surveys administered via the Cionic mobile app at onboarding and at one, three, six, nine, and 12 months. The primary endpoint, EQ-5D-5L, measures mobility, self-care, usual activities, pain, and anxiety/depression, while secondary measures track spasticity, urinary incontinence, and fatigue.

Shanghai – September 12, 2026 -- CorrectSequence Therapeutics (Correctseq) reported that its transformer Base Editor (tBE) therapy CS-101/CS-206 delivered durable clinical remission in patients with sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) across four distinct genetic backgrounds, according to a peer-reviewed study published in Cell Stem Cell on September 7, 2026.

The study, conducted with multiple research institutions, expands on earlier data showing five Chinese TDT patients treated with CS-101 all achieved transfusion independence. The new cohort includes four patients from Nigeria, Laos, Malaysia and Pakistan -- one with SCD and three with TDT -- covering genotypes βS/βS, β0/βE, and two β0/β0 variants with different mutation types.

Shanghai – September 11, 2026 -- CorrectSequence Therapeutics (Correctseq) reported that its transformer Base Editor (tBE) therapy CS-101/CS-206 achieved full transfusion independence or elimination of vaso-occlusive crises (VOC) in four new patients from Nigeria, Laos, Malaysia and Pakistan, expanding on earlier results in five Chinese patients who all reached transfusion independence. The findings, published September 7, 2026 in Cell Stem Cell, cover patients with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) carrying distinct genotypes, including βS/βS, β0/βE, and two β0/β0 variants.

Stockholm – September 11, 2026 -- SciBase Holding AB (STO: SCIB) has received an additional order worth roughly $0.6 million, or approximately SEK 5 million, from Castle Biosciences (NASDAQ: CSTL) to accelerate an ongoing clinical study and prepare a second trial under their dermatology collaboration.

Order covers Nevisense Go devices and electrodes for atopic dermatitis research

The order includes both SciBase's portable Nevisense Go pen device and associated electrodes. Deliveries are scheduled to begin in the fourth quarter of 2026.

Collaboration targets relapse prediction in atopic dermatitis patients

SciBase and Castle Biosciences entered a collaboration and license agreement in 2025. The first joint study under that agreement aims to predict relapses in atopic dermatitis and is currently underway, with the new order funding both faster progression of that trial and groundwork for a follow-up study.

Burlington, N.C. – September 11, 2026 -- Labcorp (NYSE: LH) has acquired MLM Medical Labs, a central and specialty laboratory provider with operations in the United States, Germany and South Africa, financial terms undisclosed.

Labcorp becomes the only central lab provider with wholly owned facilities on four continents

The deal extends Labcorp's laboratory footprint across North America, Europe, Asia and Africa, combining its global scale with MLM's regional laboratory network and biomarker testing capabilities. The transaction strengthens Labcorp's position as an independent central laboratory services provider for clinical trial sponsors.

Hong Kong – September 07, 2026 -- Akeso, Inc. (9926.HK) said its bispecific antibody ivonescimab produced a statistically significant and clinically meaningful overall survival benefit versus Merck's pembrolizumab in a pre-specified interim analysis of the Phase III HARMONi-2 trial, as assessed by an Independent Data Monitoring Committee.

Ivonescimab clears key secondary survival endpoint against Keytruda

The HARMONi-2 (AK112-303) study is a randomized, double-blind, multicenter registrational trial testing ivonescimab against pembrolizumab as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 at a TPS of 1% or higher. Detailed interim overall survival data will be presented at an upcoming international medical conference and published in a peer-reviewed journal.

Austin, Texas – September 7, 2026 -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has become the first center in the United States to enroll a patient in a clinical trial evaluating a next-generation pulsed field ablation mapping and ablation system for paroxysmal and persistent atrial fibrillation.

TCAI performs first US procedure under global trial protocol

Andrea Natale, M.D., executive medical director of TCAI and global principal investigator for the trial, performed the inaugural procedure. The study is designed to assess the safety and efficacy of the catheter-based system in patients with paroxysmal atrial fibrillation, defined as symptomatic episodes lasting seven days or less, and persistent atrial fibrillation, sustained arrhythmia lasting longer than one week.

Los Angeles – September 7, 2026 -- HRC Fertility, a fertility network operating 15 locations across California and Las Vegas, has appointed longtime physician Robert Boostanfar, M.D., as its first Chief Medical Officer, giving the organization a senior clinical leader as it scales operations across its 34-physician network.

Dr. Boostanfar gains oversight of clinical quality across HRC's full network

In the newly created role, Dr. Boostanfar will oversee physician engagement, clinical quality initiatives, innovation and medical performance across HRC Fertility's network of 34 physicians. He will coordinate with physicians, laboratories and clinical teams to standardize care protocols across the organization's 15 sites in the California Bay Area, Los Angeles, Orange County, San Diego County and Las Vegas.

Las Vegas – September 03, 2026 -- Paralyzed Veterans of America (PVA) opened its 2026 Healthcare Summit + Expo at the Horseshoe Hotel, drawing more than 400 healthcare professionals to advance clinical care for spinal cord injury, MS, and ALS. The event runs through September 2 and features 110 speakers and 60 exhibitors, with remarks from Department of Veterans Affairs Secretary Doug Collins.

Summit connects 400 clinicians to close gaps in SCI/D care

PVA National President Robert Thomas said healthcare for veterans with traumatic spinal cord injuries and diseases like MS and ALS extends from research through rehabilitation and long-term community life. PVA, founded in 1946, is the only nonprofit Veterans Service Organization with access inside all 25 VA SCI/D Centers, a position that has shaped its 80-year investment in research, clinical education, and advocacy.